WPD Pharmaceuticals Inc. (C:WBIO)

Business Focus: Bio Therapeutic Drugs

Get the company report for the most recent outlook updated daily

Sep 20, 2022 07:36 pm ET

WPD Pharmaceuticals Board of Directors Approved the Raise of WPD Poland's Share Capital

Vancouver, British Columbia--(Newsfile Corp. - September 20, 2022) - WPD Pharmaceuticals Inc. (CSE: WBIO) (FSE: 8SV1) (the "Company" or "WPD") a clinical-stage pharmaceutical company announces that the Company's Board of Directors (the "Board") has approved the raise of WPD Pharmaceuticals Sp. z o.o. ("WPD Poland"), the Polish subsidiary of the Company share capital from PLN 400,000 to PLN 2,100,000, that is by the amount of PLN 1,700,000, by establishment of 34,000 new, equal and indivisible shares of the nominal value of PLN 50 each and the total nominal value of PLN 1,700,000. Raise of WPD Poland's share capital is the second step of a plan to restructure WPD Poland, which the company announced on February 9, 2022.

Jul 11, 2022 12:10 pm ET

CSE Bulletin: Suspensions (MCCN, MEAL, WBIO, TELE, GBMC, CBDN)

Toronto, Ontario--(Newsfile Corp. - Le 11 juillet/July 2022) - Effective immediately, the following companies are suspended pursuant to CSE Policy 3. The suspensions are considered Regulatory Halts as defined in National Instrument 23-101 Trading Rules. Cease Trade Orders have been issued by one or more securities commissions.

Jul 11, 2022 07:44 am ET

IIROC Trading Halt - WBIO

VANCOUVER, BC, July 11, 2022 /CNW/ - The following issues have been halted by IIROC:

May 16, 2022 07:30 am ET

WPD Pharmaceuticals Signs Annex to License Agreement with Wake Forest University Health Sciences

WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is excited to announce that it has signed Annex No. 2 into its License Agreement with Wake Forest University Health Sciences...

Mar 07, 2022 07:30 am ET

WPD Pharmaceuticals Signs Consortium Agreement on EuroNanoMed Project

WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is excited to announce that it has received the final version of the signed Consortium Agreement related to the EuroNanoMed Project....

Feb 09, 2022 07:30 am ET

WPD Pharmaceuticals Announces Proposed Restructuring of Polish Subsidiary

WPD Pharmaceuticals Inc. (the “Company” or “WPD”) (CSE: WBIO) (FSE: 8SV1) announces that the Company’s board of directors (the “Board”) has approved a plan to restructure (the “Restructuring”) the outstanding capitalization of the Company’s wholly...

Feb 03, 2022 07:30 am ET

WPD Pharmaceuticals Announces Appointment of New Director

WPD Pharmaceuticals Inc. (the “Company” or “WPD”) (CSE: WBIO) (FSE: 8SV1), is pleased to announce that the Company appointed Mr. Romuald Harwas as a director of the Company, effective February 2, 2022. The appointment of Mr. Harwas filled the...

Feb 01, 2022 07:30 am ET

WPD Pharmaceuticals Secures Berubicin Sub-License Rights in Perpetuity

WPD Pharmaceuticals Inc. (the “Company” or “WPD”) (CSE: WBIO) (FSE: 8SV1), announced that in respect to its sublicense agreement with CNS Pharmaceuticals, Inc. (the “CNS Agreement”) on December 23, 2021, CNS confirmed that the Company has used...

Jan 25, 2022 07:30 am ET

WPD Pharmaceuticals Enters into Amended and Restated Sublicense Agreement with Moleculin Biotech

WPD Pharmaceuticals Inc. (the “Company” or “WPD”) (CSE: WBIO) (FSE: 8SV1), is pleased to announce that it has entered into an amended and restated sublicense agreement (the “Sublicense Agreement”) with Moleculin Biotech Inc. (“Moleculin”). On...

Dec 16, 2021 07:30 am ET

WPD Pharmaceuticals Signs Agreement with NCRD for $6.3M Grant for the Development of Liposomal Annamycin, Intended as a Treatment for AML

WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is pleased to announce that it was informed that the Polish National Center for Research and Development (“NCRD”) has signed an...

Oct 01, 2021 07:30 am ET

WPD Pharmaceuticals Announces AGSM Results

WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, announces the results of its annual general and special meeting held September 29, 2021 in Vancouver, Canada. Re-elected as directors...

Sep 02, 2021 07:30 am ET

WPD Pharmaceuticals Announces AGM September 29; Plans Different Path to Fundraising Through Delisting; WPD Poland Arranges Additional Loans; Communications Consultant in Poland

WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, announces that it will hold its Annual and Special General Meeting of Shareholders (AGSM) on September 29, 2021 in Vancouver, Canada...

Jul 12, 2021 07:30 am ET

WPD Pharmaceuticals’ Licensor Receives FDA Fast Track Designation for Berubicin for the Treatment of Recurrent Glioblastoma Multiforme; WPD Poland Arranges Loans

WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is pleased to announce that CNS Pharmaceuticals Inc. (“CNS”) (NASDAQ:CNSP), the company that licenses the drug candidate Berubicin to...

Jun 28, 2021 07:30 am ET

WPD Pharmaceuticals Plans to Commence Phase Ib/II Study of Berubicin for the Treatment of Glioblastoma in 2H 2021

WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, today provided an update on its Berubicin drug candidate clinical development program for the treatment of glioblastoma multiforme...

Jun 10, 2021 07:30 am ET

WPD Pharmaceuticals Invited to Join International Research Consortium

WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is excited to announce that it has been invited to be a member of an international consortium of leading industry experts researching...

May 14, 2021 04:30 pm ET

WPD Pharmaceuticals Provides Update on Audited Financial Statements

WPD Pharmaceuticals Inc. (the “Company”) (CSE: WBIO) (FSE: 8SV1), provides this update on the status of the audit of its consolidated annual financial statements for the year ended December 31, 2020 (the “2020 Financial Statements”), the management...

May 11, 2021 07:30 am ET

WPD Pharmaceuticals to Receive $6.7 Million Grant for Development of Annamycin Drug Candidate

WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is pleased to announce that it has been conditionally awarded a grant of $6,730,036 (20,394,049.68 PLN) from the Polish National...

May 05, 2021 12:26 pm ET

WPD Pharmaceuticals Receives Approval for Temporary Management Cease Trade Order for Late Filing of Audited Annual Financial Statements

WPD Pharmaceuticals Inc. (the “Company”) (CSE: WBIO) (FSE: 8SV1), announces that further to its news release dated April 29, 2021 it has received approval from the British Columbia Securities Commission for a temporary management cease trade order...

Apr 29, 2021 08:55 am ET

WPD Pharmaceuticals Announces Application for a Management Cease Trade Order For Late Filing of Audited Annual Financial Statements

WPD Pharmaceuticals Inc. (the “Company”) (CSE: WBIO) (FSE: 8SV1), the Company announces that it has made an application to the British Columbia Securities Commission to approve a temporary management cease trade order (“MCTO”) under National Policy...

Apr 27, 2021 07:30 am ET

WPD Pharmaceuticals to Attend the 10th Congress of the Polish Society of Pediatric Oncology and Hematology and Present Assumption of the Phase 1 Study with Berubicin in Pediatric Malignant Gliomas

WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is pleased to announce that it will attend the 10th Annual Congress of the Polish Society of Pediatric Oncology and Hematology to be...

Apr 13, 2021 07:30 am ET

WPD Pharmaceuticals and IAG to Host a Joint Webinar, “The Potential of Advanced Imaging to Show the Early Treatment Effects of Berubicin in Brain Cancer”

WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is pleased to announce that it will be participating in an upcoming webinar “The Potential of Advanced Imaging to Show the Early...

Apr 06, 2021 07:30 am ET

WPD Pharmaceuticals Holds Pre-Submission Meeting with the European Medicines Agency and Receives Second Prepayment of C$954,248 From a Total C$7.4 Million Grant for Development of Berubicin

WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is pleased to announce that it has received prepayment of approximately C$954,248 (3,000,000 PLN) from the Polish National Center for...

Mar 30, 2021 07:30 am ET

WPD Pharmaceuticals Announces Amended Sublicense Agreement with Moleculin Biotech for WP1066, WP1122 and Annamycin Drug Candidates

WPD Pharmaceuticals Inc. (“WPD” or the “Company”) (CSE: WBIO) (FSE: 8SV1), a clinical stage pharmaceutical company, is pleased to announce that is has entered into an amended and restated sublicense agreement with Moleculin Biotech Inc....

Mar 16, 2021 07:30 am ET

WPD Pharmaceuticals Engages World-Renowned Paediatric Oncology Expert to Support Glioblastoma Programs for WPD101

WPD Pharmaceuticals Inc. (“WPD” or the “Company”) (CSE: WBIO) (FSE: 8SV1), a clinical stage pharmaceutical company, is pleased to announce that it has engaged Paediatric Oncology expert, Prof. David Walker to support and develop preclinical and...

Feb 24, 2021 07:30 am ET

WPD Pharmaceuticals Announces Berubicin Supply Agreement for the Upcoming Clinical Trials

WPD Pharmaceuticals (CSE:WBIO) (8SV1.F) ("WPD" or the “Company”) today announced that it has signed an agreement with CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) (“CNS”) to obtain Investigational Medicinal Product (“IMP”) for use in the planned...

Feb 18, 2021 09:05 am ET

WPD and CNS Pharmaceuticals Announce Positive Opinion of the Polish Central Ethics Committee for the WPD-201 Study and Central IRB Study Level Approval for the CNS-201 Study

WPD Pharmaceuticals (CSE:WBIO) (8SV1.F) ("WPD") and CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), biopharmaceutical companies specializing in the development of novel treatments for primary and metastatic cancers of the brain...

Feb 18, 2021 08:05 am ET

WPD and CNS Pharmaceuticals Announce Positive Opinion of the Polish Central Ethics Committee for the WPD-201 Study and Central IRB Study Level Approval for the CNS-201 Study

HOUSTON, Feb. 18, 2021 /PRNewswire/ -- WPD Pharmaceuticals (CSE:WBIO) (8SV1.F) ("WPD") and CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), biopharmaceutical companies specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that WPD Pharmaceuticals received a positive opinion of the Lower Silesian Medical Chamber Ethics Committee in Wrocław, Poland for its planned upcoming Berubicin clinical trial in adults with Glioblastoma Muliforme (GBM) under the WPD-201 Clinical Trial Protocol. CNS

Feb 11, 2021 07:30 am ET

WPD Pharmaceuticals Engages Worldwide Clinical Trials as CRO for Further Support on Berubicin Trials

WPD Pharmaceuticals Inc. (“WPD” or the “Company”) (CSE: WBIO) (FSE: 8SV1), a clinical stage pharmaceutical company, is pleased to announce that it has signed another services agreement with world-renowned Contract Research Organization (“CRO”),...

Feb 09, 2021 07:30 am ET

WPD Pharmaceuticals Announces US$1.5M Grant Awarded to Polish Research Institute for Independent Clinical Trial of Annamycin

WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company is pleased to announce that the Agencja Badań Medycznych (The Medical Research Agency) a Polish state agency responsible for...

Feb 05, 2021 07:30 am ET

WPD Pharmaceuticals’ Licensor Announces 100% Survival Achieved in Osteosarcoma Lung Metastases Animal Model of Annamycin Drug

WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is pleased to announce that that Moleculin Biotech Inc. (NASDAQ:MBRX) (“Moleculin”), the company that sublicenses the compound...

Jan 28, 2021 07:30 am ET

WPD Pharmaceuticals to Participate in the 7ᵗʰ Annual LSX World Congress, a Leading Global Healthcare and Life Sciences Forum

WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is pleased to announce that it will be participating in the LSX World Congress from February 1 – 5, 2021. Senior Management will be...

Jan 14, 2021 07:30 am ET

WPD Pharmaceuticals Contracts Clinigen Clinical Supplies Management to Perform QP Certification of Berubicin for the Clinical Trials Authorization

WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is pleased to announce that it has signed a contract with Clinigen Clinical Supplies Management (“Clinigen”), a leading clinical...

Jan 06, 2021 07:30 am ET

WPD Pharmaceuticals to Collaborate With IAG to Deploy Artificial Intelligence and Quantitative Imaging to Assess the Effects of Berubicin

WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is pleased to announce that it has engaged Image Analysis Group (“IAG”), a leading medical imaging company, to provide important...

Oct 26, 2020 07:30 am ET

WPD Pharmaceuticals Provides Update On Berubicin Drug Candidate in Celebration of National Brain Cancer Day in Canada

WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is pleased to provide an update on the development of its licensed Berubicin drug candidate in celebration of National Brain Cancer...

Oct 15, 2020 07:30 am ET

WPD Pharmaceuticals Appoints New Chief Medical Officer to Lead Phase I and II Clinic Trials

WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is pleased to announce that it has appointed Marek Sipowicz MD PhD, as Chief Medical Officer (“CMO”) of the Company. Marek brings over...

Oct 05, 2020 07:30 am ET

WPD Pharmaceuticals Receives the First Prepayment of $705,000 from Total $7.4 Million Grant for Development of Berubicin, and Receives $106,626 Government Covid-19 Cash Assistance

WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is pleased to announce that it has received a prepayment of approximately C$705,000 (2,000,000 PLN) and is waiting for approval of...

Sep 16, 2020 07:30 am ET

WPD Pharmaceuticals Receives Second Prepayment of $705,000 from Total $7.4 Million Grant for Development of WPD101

Sep 09, 2020 07:30 am ET

WPD Pharmaceuticals Engages Worldwide Clinical Trials as CRO for Phase 2 Berubicin Trials

WPD Pharmaceuticals Inc. (“WPD” or the “Company”) (CSE: WBIO) (FSE: 8SV1), a clinical stage pharmaceutical company, is pleased to announce that is has engaged world-renowned Contract Research Organization (“CRO”), Worldwide Clinical Trials (“WCT”)...

Sep 01, 2020 07:59 am ET

WPD Pharmaceuticals Announces New Publication Demonstrating Highly Effective Anticancer Therapy in Animals with Spontaneous Tumors using WPD101 Drug Candidate

WPD Pharmaceuticals Inc. (“WPD” or the “Company”) (CSE: WBIO) (FSE: 8SV1), a clinical stage pharmaceutical company, is excited to announce that a recently published study confirms the high therapeutic potential of IL-13RA2- and EphA2...

Aug 17, 2020 09:52 am ET

WPD Pharmaceuticals Enters into Collaborative Agreement for WP1122, Receives Supply and Appoints New CFO

WPD Pharmaceuticals Inc. (“WPD” or the “Company”) (CSE: WBIO) (FSE: 8SV1), a clinical stage pharmaceutical company, announces that it has entered into a collaborative agreement with Dermin Sp. z o.o., a Polish biotech research company. WPD...

Jul 28, 2020 07:30 am ET

WPD Pharmaceuticals Provides Update on WPD101, a Drug Candidate Targeting GBM Tumors

WPD Pharmaceuticals Inc. (“WPD” or the “Company”) (CSE: WBIO) (FSE: 8SV1), a clinical stage pharmaceutical company, in celebration of last week’s National glioblastoma multiforme (“GBM”) day in the United States, is pleased to provide an update on...

Jul 23, 2020 07:30 am ET

WPD Pharmaceuticals Licensor Announces New Independent In Vitro Testing Confirms Antiviral Activity of WP1122 in Coronavirus

WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”), a clinical stage pharmaceutical company, is pleased to announce that Moleculin Biotech Inc. (“Moleculin”), the company that sublicenses the compound WP1122 to WPD for 29...

Jul 06, 2020 07:30 am ET

WPD Pharmaceuticals Licensor Announces Updates on Annamycin and WP1066

Jun 22, 2020 07:00 am ET

WPD Pharmaceuticals Licensor Announces Confirmatory in Vitro Analysis of WP1122

May 28, 2020 07:30 am ET

WPD Pharmaceuticals Licensor Granted Another Key Patent for the Development of WPD101 Drug Candidate

WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”), a clinical stage pharmaceutical company, is pleased to announce that on May 21, 2020 Wake Forest University received a patent from the United States Patent and Trademark...

May 15, 2020 04:17 pm ET

IIROC Trade Resumption - WBIO

VANCOUVER, May 15, 2020 /CNW/ - Trading resumes in:

May 15, 2020 12:24 pm ET

WPD Pharmaceuticals To Resume Trading

WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical stage pharmaceutical company, announces that its listed shares will resume trading on the CSE Exchange in Canada at the open on Tuesday, May 19, 2020. Markets are...

May 05, 2020 04:01 pm ET

WPD Pharmaceuticals Comments on SEC Order

WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical stage pharmaceutical company, clarifies the temporary suspension on its trading ordered by the United States Securities and Exchange Commission (“SEC”). After...

May 04, 2020 02:02 pm ET

IIROC Trading Halt - WBIO

VANCOUVER, May 4, 2020 /CNW/ - The following issues have been halted by IIROC:

Apr 30, 2020 08:00 am ET

WPD Pharmaceuticals and CNS Pharmaceuticals Identify Leading Polish Medical Institutions for Berubicin Phase 2 Clinical Trial

WPD Pharmaceuticals Inc. (CSE: WBIO) (FSE: 8SV1) (the “Company” or “WPD”) a clinical stage pharmaceutical company, is pleased to announce that in collaboration with CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS"), a biopharmaceutical company, it...

Apr 30, 2020 08:00 am ET

CNS Pharmaceuticals and WPD Pharmaceuticals Identify Leading Polish Medical Institutions for Berubicin Phase 2 Clinical Trial

HOUSTON, April 30, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system in collaboration with WPD Pharmaceuticals Inc. (CSE:WBIO) (8SV1.F) ("WPD") a clinical stage pharmaceutical company, today announced it has identified several leading medical institutions in Poland to conduct its Berubicin Phase 2 clinical trial in adults with glioblastoma multiforme ("GBM"), an aggressive and incurable form of brain c

Apr 29, 2020 03:05 am ET

WPD Pharmaceutical’s Annamycin Drug Approved for Accelerated European Clinical Trial

WPD Pharmaceuticals Inc. (CSE: WBIO) (FSE: 8SV1) (the “Company” or “WPD”) a clinical stage pharmaceutical company is pleased to announce that through its license partner, Moleculin Biotech, Inc. (NASDAQ: MBRX) ("Moleculin"), it has been authorized...

Apr 24, 2020 03:05 am ET

WPD Pharmaceuticals Announces FDA Application Under The Orphan Drug Act Was Submitted By License Partner for Brain Cancer Drug, Berubicin

WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical stage pharmaceutical company is pleased to announced that its license partner, CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS") filed an application with the U.S....

Apr 23, 2020 03:05 am ET

WPD Pharmaceuticals’ Annamycin Drug Candidate Meets Endpoint in Successful U.S. Phase 1 AML Trial With No Evidence of Cardiotoxicity

WPD Pharmaceuticals Inc. (CSE: WBIO) (FSE: 8SV1) (the “Company” or “WPD”) a clinical stage pharmaceutical company is pleased to provide an update on its Annamycin drug candidate. Through its license partner, Moleculin Biotech, Inc. (Nasdaq: MBRX)...

Apr 21, 2020 07:00 am ET

WPD Pharmaceuticals and CNS Pharmaceuticals Announce Additional Coronavirus Testing on WP1122 by ImQuest Biosciences

WPD Pharmaceuticals Inc. (CSE: WBIO) (FSE: 8SV1) (the “Company” or “WPD”) a clinical stage pharmaceutical company along with its development partner CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“CNS”), announce that ImQuest Biosciences has been...

Apr 16, 2020 03:05 am ET

WPD Pharmaceuticals’ License Partner, Moleculin Biotech to Host Conference Call to Discuss COVID-19 Potential in WP1122 Drug Candidate

WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical stage pharmaceutical company announces that its license partner, Moleculin Biotech, Inc. (“Moleculin”) will be hosting a web-based investor conference call, today,...

Apr 13, 2020 08:00 am ET

CNS Pharmaceuticals Announces Independent University Research Confirms Active Compound in WP1122 Completely Prevents Coronavirus Replication In Vitro; WP1122 is Subject to Development Agreement with W

HOUSTON, April 13, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biotechnology company specializing in the development of novel treatments for brain tumors, announced that independent research by the University of Frankfurt found 2-deoxy-D-glucose ("2-DG") to reduce replication of SARS-CoV-2, the virus that causes COVID-19, by 100% in in vitro testing.

Apr 13, 2020 03:05 am ET

WPD Pharmaceuticals to Resume Trading on Monday, April 13, 2020

WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical stage pharmaceutical company reports that the Company anticipates to resume trading at market open on Monday, April 13, 2020. About WPD Pharmaceuticals WPD is a...

Apr 09, 2020 04:37 pm ET

IIROC Trade Resumption - WBIO

VANCOUVER, April 9, 2020 /CNW/ - Trading resumes in:

Apr 09, 2020 03:31 pm ET

WPD Pharmaceuticals Clarifies News on Licensed Drug Candidate

WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical stage pharmaceutical company, at the request of IIROC, clarifies its press release released yesterday regarding the independent research on its WP1122 drug...

Apr 09, 2020 08:43 am ET

IIROC Trading Halt - WBIO

VANCOUVER, April 9, 2020 /CNW/ - The following issues have been halted by IIROC:

Apr 09, 2020 03:05 am ET

WPD Pharmaceuticals Reports Active Compound in Licensed Drug Candidate Reduces Coronavirus Replication in Vitro by 100%

WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical stage pharmaceutical company, is pleased to announce that independent research on its WP1122 drug compound found 2-deoxy-D-glucose (“2-DG”) to reduce replication of...

Apr 08, 2020 03:05 am ET

WPD Pharmaceuticals Provides Corporate Update

WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”), a clinical stage pharmaceutical company, is pleased to provide a corporate update on its business and the continued development of its portfolio of drug candidates....

Apr 01, 2020 03:05 am ET

WPD Pharmaceuticals Welcome Dr. Waldemar Debinski to its Scientific Advisory Board

WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical stage pharmaceutical company, is excited to announce that Dr. Waldemar Debinski, inventor of WPD101, WPD102 and WPD103 drug candidates has joined its Scientific...

Mar 24, 2020 03:05 am ET

WPD Pharmaceuticals Partners with CNS Pharmaceuticals on Drug Development for Coronavirus and Other Antiviral Indications

WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical stage pharmaceutical company, announces it has entered into a development agreement (the “Agreement”) with CNS Pharmaceuticals, Inc. (“CNS”)(NASDAQ:CNSP) for the...

Mar 23, 2020 08:00 am ET

CNS Pharmaceuticals Signs Agreement with WPD Pharmaceuticals to Develop Drug Candidates for a Range of Viruses including Coronavirus for International Markets

HOUSTON, March 23, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company primarily specializing in the development of novel treatments for cancers of the brain and central nervous system, announces it has entered into an agreement with WPD Pharmaceuticals Inc. (CSE: WBIO) for the development of several preclinical drug candidates including WP1122, which is being tested on a range of viruses including the coronavirus SARS-CoV-2. WPD Pharmaceuticals previously licensed rights to a portfolio of drug candidates, including WP1122, from

Mar 19, 2020 03:05 am ET

WPD PHARMACEUTICALS’ WP1122 DRUG TO BE TESTED ON A RANGE OF VIRUSES INCLUDING CORONAVIRUS

WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical stage pharmaceutical company, announces, that its license partner Moleculin Biotech, Inc. (Nasdaq: MBRX)(“Moleculin”), has entered into an agreement with a leading...

Mar 16, 2020 09:30 am ET

WPD PHARMACEUTICALS ANNOUNCES BRAIN CANCER PATIENT FROM BERUBICIN PHASE 1 TRIAL REMAINS CANCER FREE

WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical stage pharmaceutical company, is pleased to announce that a patient from the Phase 1 clinical trial of its Berubicin drug for the treatment of glioblastoma...

Mar 13, 2020 04:05 pm ET

WPD PHARMACEUTICALS ANNOUNCES BRAIN CANCER PATIENT FROM BERUBICIN PHASE 1 TRIAL REMAINS CANCER FREE

Mar 11, 2020 04:05 pm ET

WPD PHARMACEUTICALS RECEIVED $800,000 REIMBURSEMENT FROM $7.4 MILLION GOVERNMENT GRANT FOR DEVELOPMENT OF GLIOBLASTOMA DRUG

WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical stage pharmaceutical company, is pleased to announce that it has received from the Polish National Center for Research and Development (“NCRD”) approximately...

Mar 04, 2020 03:05 am ET

WPD Pharmaceuticals’ Brain Cancer Drug Received Positive FDA Pre-IND Guidance

WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”), a clinical stage pharmaceutical company, is pleased to provide an update that through its license partner, CNS Pharmaceuticals, Inc. (“CNS”)(Nasdaq:CNSP), it received...

Feb 27, 2020 03:05 am ET

WPD Pharmaceuticals’ Annamycin Received Positive Interim Results From Phase 1/2 Clinical Studies in Acute Myeloid Leukemia

WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”), a clinical stage pharmaceutical company is pleased to provide an update on the clinical drug studies of Annamycin in Acute Myeloid Leukemia (“AML”). WPD’s license partner...

Feb 24, 2020 03:05 am ET

WPD Pharmaceuticals Granted Key Patent Exclusively Licensed From Wake Forest University

WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”), a clinical stage pharmaceutical company, is pleased to announce that on February 6, 2020 Wake Forest University (“Wake Forest”) received a notice of allowance from the United...

Feb 20, 2020 03:05 am ET

WPD Pharmaceuticals' STAT3 Inhibitor Received FDA Approval of IND Status in Pediatric Brain Cancer Trial

WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”), a clinical stage pharmaceutical company is pleased to provide an update on its WP1066 drug in the treatment of pediatric brain cancer. Through Moleculin Biotech, Inc....

Feb 18, 2020 07:35 am ET

WPD Pharmaceuticals’ WP1220 Drug Demonstrates Median Reduction of 56% in Skin Cancer Lesions in Clinical Trials

WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”), a clinical stage pharmaceutical company, in collaboration with license partner, Moleculin Biotech, Inc. (“Moleculin”)(Nasdaq: MBRX) is pleased to announce the final data from...

Feb 12, 2020 03:05 am ET

WPD Pharmaceuticals to Conduct Clinical Trials in Pediatric Brain Tumors Through Collaboration With CNS Pharmaceuticals

WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”), a clinical stage pharmaceutical company, is pleased to announce its plan to initiate a Phase I clinical trial for Berubicin in pediatric brain cancer in Poland in...

Feb 10, 2020 03:05 am ET

WPD Pharmaceuticals’ WP1066 Drug Candidate Had Breakthrough Discovery

WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”), a clinical stage pharmaceutical company, is pleased to announce that its drug candidate WP1066 was the subject of a scientific paper published in 2019 entitled "Immunological...

Feb 05, 2020 03:05 am ET

WPD Pharmaceuticals’ Annamycin Drug Received FDA Approval of Fast Track Designation

WPD Pharmaceuticals Inc. (CSE: WBIO) (FSE: 8SV1) (the “Company” or “WPD”), a clinical stage pharmaceutical company, is pleased to provide an update on its Annamycin Drug. Through its development partner, Moleculin Biotech, Inc. (Nasdaq: MBRX)...

Feb 03, 2020 03:05 am ET

WPD Pharmaceuticals Completed the Acquisition of Two Drug Candidates Bringing Total Development Funding Spent on Drugs Under License to Over USD $100 Million

WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”), a clinical stage pharmaceutical company, provides an update on the completed acquisition of exclusive sublicenses for two drug candidates from Moleculin Biotech, Inc. a...

Jan 31, 2020 04:05 pm ET

Ad blocking detected

You've reached your 10 company page visit this month!

WPD Pharmaceuticals Inc. (C:WBIO)

Business Focus: Bio Therapeutic Drugs